Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...

Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...

NEW YORK-- ( BUSINESS WIRE )--Hess Corporation (NYSE: HES) announced today that John Hess, Chief Executive Officer, will ...

On Monday, TransUnion (TRU) stock saw a modest uptick, ending the day at $96.93 which represents a slight increase of $1.27 or 1.33% from the prior close of $95.66. The stock opened at $95.91 and ...

Wolfe Research downgraded Matson (MATX) to Peer Perform from Outperform. The firm cites valuation for the downgrade. Matson has materially ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...

On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte ...

Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following recent share pullback, a new management team, and robust ...